J Case Rep Images Oncology 2016;2:71–73.
FIRST PARAGRAPH: A 47-year-old female presented with high-risk myelodysplastic syndrome (MDS) without detectable cytogenetic abnormality from the bone marrow specimen. Initially, she received azacytidine while awaiting bone marrow transplantation (BMT). After successful allogeneic BMT from a mismatched related donor, she received post-transplant care including management of transplant-related toxicity and skin manifestations of graft versus host disease (GVHD) in a designated BMT center. Subsequent bone marrow showed no evidence of MDS, and she is currently free from GVHD.
Article Size: <1 MB